Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Santhosh Dhanraj is active.

Publication


Featured researches published by Santhosh Dhanraj.


Journal of Medical Genetics | 2015

Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes

Ibrahim Ghemlas; Hongbing Li; Bozana Zlateska; Robert J. Klaassen; Conrad V. Fernandez; Rochelle Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeff H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark J. Belletrutti; Vicky R. Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Santhosh Dhanraj; Emma Reble; Amanda Wagner; Joseph Beyene; Peter N. Ray; Stephen Meyn; Michaela Cada; Yigal Dror

Background Phenotypic overlap among the inherited bone marrow failure syndromes (IBMFSs) frequently limits the ability to establish a diagnosis based solely on clinical features. >70 IBMFS genes have been identified, which often renders genetic testing prolonged and costly. Since correct diagnosis, treatment and cancer surveillance often depend on identifying the mutated gene, strategies that enable timely genotyping are essential. Methods To overcome these challenges, we developed a next-generation sequencing assay to analyse a panel of 72 known IBMFS genes. Cases fulfilling the clinical diagnostic criteria of an IBMFS but without identified causal genotypes were included. Results The assay was validated by detecting 52 variants previously found by Sanger sequencing. A total of 158 patients with unknown mutations were studied. Of 75 patients with known IBMFS categories (eg, Fanconi anaemia), 59% had causal mutations. Among 83 patients with unclassified IBMFSs, we found causal mutations and established the diagnosis in 18% of the patients. The assay detected mutant genes that had not previously been reported to be associated with the patient phenotypes. In other cases, the assay led to amendments of diagnoses. In 20% of genotype cases, the results indicated a cancer surveillance programme. Conclusions The novel assay is efficient, accurate and has a major impact on patient care.


Journal of Medical Genetics | 2015

Bone marrow failure and developmental delay caused by mutations in poly(A)-specific ribonuclease (PARN)

Santhosh Dhanraj; Sethu Madhava Rao Gunja; Adam Deveau; Mikael Nissbeck; Boonchai Boonyawat; Andrew J. Coombs; Alessandra Renieri; Mafalda Mucciolo; Annabella Marozza; Sabrina Buoni; Lesley Turner; Hongbing Li; Ameer Jarrar; Mathura Sabanayagam; Melanie Kirby; Mary Shago; Dalila Pinto; Jason N. Berman; Stephen W. Scherer; Anders Virtanen; Yigal Dror

Background Deadenylation regulates RNA function and fate. Poly(A)-specific ribonuclease (PARN) is a deadenylase that processes mRNAs and non-coding RNA. Little is known about the biological significance of germline mutations in PARN. Methods We identified mutations in PARN in patients with haematological and neurological manifestations. Genomic, biochemical and knockdown experiments in human marrow cells and in zebrafish have been performed to clarify the role of PARN in the human disease. Results We identified large monoallelic deletions in PARN in four patients with developmental delay or mental illness. One patient in particular had a severe neurological phenotype, central hypomyelination and bone marrow failure. This patient had an additional missense mutation on the non-deleted allele and severely reduced PARN protein and deadenylation activity. Cells from this patient had impaired oligoadenylation of specific H/ACA box small nucleolar RNAs. Importantly, PARN-deficient patient cells manifested short telomeres and an aberrant ribosome profile similar to those described in some variants of dyskeratosis congenita. Knocking down PARN in human marrow cells and zebrafish impaired haematopoiesis, providing further evidence for a causal link with the human disease. Conclusions Large monoallelic mutations of PARN can cause developmental/mental illness. Biallelic PARN mutations cause severe bone marrow failure and central hypomyelination.


Blood | 2017

Biallelic Mutations in DNAJC21 Cause Shwachman-Diamond Syndrome

Santhosh Dhanraj; Anna Matveev; Hongbing Li; Supanun Lauhasurayotin; Lawrence Jardine; Michaela Cada; Bozana Zlateska; Chetankumar S. Tailor; Joseph Zhou; Roberto Mendoza-Londono; Ajoy Vincent; Peter R. Durie; Stephen W. Scherer; Johanna M. Rommens; Elise Héon; Yigal Dror

Program in Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Marrow Failure and Myelodysplasia Program, Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology Oncology, Children’s Hospital of Western Ontario, London, ON, Canada; Division of Clinical and Metabolic Genetics, Department of Ophthalmology and Vision Sciences, and Division of Gastroenterology and Nutrition, The


Journal of Pediatric Hematology Oncology | 2010

Proximal radio-ulnar synostosis with bone marrow failure syndrome in an infant without a HOXA11 mutation.

Paul Castillo-Caro; Santhosh Dhanraj; Paul R. Haut; Kent A. Robertson; Yigal Dror; Anjali A. Sharathkumar

SUMMARY This report summarizes the clinical management of an infant with a proximal radio-ulnar synostosis and inherited bone marrow failure syndrome (PRUS/IBMFS). Molecular studies were negative for the characteristic HOXA11 mutation described earlier. He was successfully treated with a non-myeloablative hematopoietic stem cell transplantation from an human leukocyte antigen-identical sibling donor at the age of 3 months. We reviewed the literature on PRUS/IBMFS with an emphasis on the current understanding of the molecular mechanisms involved in the disease pathogenesis. Absence of the HOXA11 mutation in this case implies that molecular mechanisms beyond the HOXA11 gene, yet to be discovered, may contribute for the development of PRUS/IBMFS.


Journal of Clinical Immunology | 2013

Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia

Boonchai Boonyawat; Santhosh Dhanraj; Fahad al Abbas; Bozana Zlateska; Eyal Grunenbaum; Chaim M. Roifman; Leslie Steele; Stephen Meyn; Victor S. Blanchette; Stephen W. Scherer; Sabina Swierczek; Josef T. Prchal; Qili Zhu; Troy R. Torgerson; Hans D. Ochs; Yigal Dror

ObjectiveDisorders linked to mutations in the X chromosomes typically affect males. The aim of the study is to decipher the mechanism of disease expression in a female patient with a heterozygous mutation on the X-chromosome.Patients and MethodsClinical data was extracted from the Canadian Inherited Marrow Failure Registry. Genomic ribonucleic acid (DNA) and complementary DNA (cDNA) underwent Sanger sequencing. Protein analysis was performed by flow cytometry. X-inactivation patterns were analyzed by evaluating the DNA methylation status and cDNA clonal expression of several genes on the X-chromosome. SNP array was used for molecular karyotyping of the X-chromosome.ResultsA female with thrombocytopenia, eczema and mild T-lymphocyte abnormalities with extensive negative diagnostic testing, was suspected to have Wiskott-Aldrich syndrome (WAS)/X-linked thrombocytopenia. Although the girl had a mutation (c.397G > A, p.E133K) in only one allele, she was found to have an extremely skewed X-inactivation pattern and no expression of the WAS protein. Family studies using DNA methylation analysis and cDNA clonal expression of several genes on the X-chromosome demonstrated that the patient developed de-novo non-random inactivation of the X-chromosome that does not carry the mutation. Genome-wide high-density molecular karyotyping excluded deletions and amplifications as a cause for the non-random inactivation of one X-chromosome.ConclusionsOur study emphasizes the need to test selected female patients with complete or incomplete disease expression for X-linked disorders even in the absence of a family history.


Pediatric Blood & Cancer | 2013

Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome†‡

Santhosh Dhanraj; Arif Manji; Dalila Pinto; Stephen W. Scherer; Helen Favre; Mignon L. Loh; Runjan Chetty; Alice C. Wei; Yigal Dror

Shwachman‐Diamond syndrome (SDS) is characterized by hypoplasia of the bone marrow and exocrine pancreas and a high risk of leukemia. It is unknown whether solid tumors are part of the disease phenotype.


npj Genomic Medicine | 2017

The Clinical Impact of Copy Number Variants in Inherited Bone Marrow Failure Syndromes

Nicolas Waespe; Santhosh Dhanraj; Manju Wahala; Elena Tsangaris; Tom Enbar; Bozana Zlateska; Hongbing Li; Robert J. Klaassen; Conrad V. Fernandez; Geoff D.E. Cuvelier; John K. Wu; Yves Pastore; Mariana Silva; Jeffrey H. Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark J. Belletrutti; Vicky R. Breakey; Lawrence Jardine; Lisa Goodyear; Liat Kofler; Michaela Cada; Lillian Sung; Mary Shago; Stephen W. Scherer; Yigal Dror

Inherited bone marrow failure syndromes comprise a genetically heterogeneous group of diseases with hematopoietic failure and a wide array of physical malformations. Copy number variants were reported in some inherited bone marrow failure syndromes. It is unclear what impact copy number variants play in patients evaluated for a suspected diagnosis of inherited bone marrow failure syndromes. Clinical and genetic data of 323 patients from the Canadian Inherited Marrow Failure Registry from 2001 to 2014, who had a documented genetic work-up, were analyzed. Cases with pathogenic copy number variants (at least 1 kilobasepairs) were compared to cases with other mutations. Genotype-phenotype correlations were performed to assess the impact of copy number variants. Pathogenic nucleotide-level mutations were found in 157 of 303 tested patients (51.8%). Genome-wide copy number variant analysis by single-nucleotide polymorphism arrays or comparative genomic hybridization arrays revealed pathogenic copy number variants in 11 of 67 patients tested (16.4%). In four of these patients, identification of copy number variant was crucial for establishing the correct diagnosis as their clinical presentation was ambiguous. Eight additional patients were identified to harbor pathogenic copy number variants by other methods. Of the 19 patients with pathogenic copy number variants, four had compound-heterozygosity of a copy number variant with a nucleotide-level mutation. Pathogenic copy number variants were associated with more extensive non-hematological organ system involvement (p = 0.0006), developmental delay (p = 0.006) and short stature (p = 0.04) compared to nucleotide-level mutations. In conclusion, a significant proportion of patients with inherited bone marrow failure syndromes harbor pathogenic copy number variants which were associated with a more extensive non-hematological phenotype in this cohort. Patients with a phenotype suggestive of inherited bone marrow failure syndromes but without identification of pathogenic nucleotide-level mutations should undergo specific testing for copy number variants.Blood disorders: impact of genomic structural variationCopy number variation in patients with inherited bone marrow failure syndromes (IBMFSs) is associated with more severe clinical symptoms. In addition to persistently low levels of red blood cells, white blood cells and/ or platelets, patients with IBMFSs also present varying degrees of physical malformations. Most cases are associated with single base-pair mutations in the DNA sequence, but Canadian researchers led by Yigal Dror at The Hospital for Sick Children in Toronto, have found that whole sections of the genome are deleted or repeated in an important proportion of patients. Those carrying copy number variants (CNV) presented more commonly with developmental delay, short stature and defects in more organ systems, than patients with point mutations. CNV analysis of patients with suspected IBMFSs could aid early disease evaluation and management.


Journal of Medical Genetics | 2018

Biallelic mutations in EXOC3L2 cause a novel syndrome that affects the brain, kidney and blood

Adel Shalata; Supanun Lauhasurayotin; Z. Leibovitz; Hongbing Li; Diane Hebert; Santhosh Dhanraj; Yarin Hadid; Mohammed Mahroum; Jacob Bajar; Sandro Egenburg; Ayala Arad; Mordechai Shohat; Sami Haddad; Hassan Bakry; Houtan Moshiri; Stephen S Scherer; Shay Tzur; Yigal Dror

Background Dandy-Walker malformation features agenesis/hypoplasia of the cerebellar vermis, cystic dilatation of the fourth ventricle and enlargement of posterior fossa. Although Dandy-Walker malformation is relatively common and several genes were linked to the syndrome, the genetic cause in the majority of cases is unknown. Objective To identify the mutated gene responsible for Dandy-Walker malformation, kidney disease and bone marrow failure in four patients from two unrelated families. Methods Medical assessment, sonographic, MRI and pathological studies were used to define phenotype. Chromosomal microarray analysis and whole-exome sequence were performed to unravel the genotype. Results We report four subjects from two unrelated families with homozygous mutations in the Exocyst Complex Component 3-Like-2 gene (EXOC3L2).EXOC3L2 functions in trafficking of post-Golgi vesicles to the plasma membrane. In the first family a missense mutation in a highly conserved amino acid, p.Leu41Gln, was found in three fetuses; all had severe forms of Dandy-Walker malformation that was detectable by prenatal ultrasonography and confirmed by autopsy. In the second family, the affected child carried a nonsense mutation, p.Arg72*, and no detected protein. He had peritrigonal and cerebellar white matter abnormalities with enlargement of the ventricular trigones, developmental delay, pituitary hypoplasia, severe renal dysplasia and bone marrow failure. Conclusion We propose that biallelic EXOC3L2 mutations lead to a novel syndrome that affects hindbrain development, kidney and possibly the bone marrow.


Blood | 2015

Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes

Nicolas Waespe; Santhosh Dhanraj; Manju Wahala; Tom Enbar; Bozana Zlateska; Hongbing Li; Robert J. Klaassen; Conrad V. Fernandez; Rochelle Yanofsky; John K. Wu; Yves Pastore; Mariana Silva; Jeffrey H. Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark J. Belletrutti; Vicky R. Breakey; Lawrence Jardine; Lisa Goodyear; Liat Kofler; Ibrahim Ghemlas; Michaela Cada; Lillian Sung; Mary Shago; Stephen W. Scherer; Yigal Dror


Blood | 2015

The Zebrafish Provides Mechanistic Insights into the Role of Poly(A)-Specific Ribonuclease ( PARN ) in Hematopoietic Stem Cell (HSC) Homeostasis and Bone Marrow Failure

Adam P Deveau; Andrew J Coombs; Santhosh Dhanraj; Gretchen Wagner; Yigal Dror; Jason N. Berman

Collaboration


Dive into the Santhosh Dhanraj's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen W. Scherer

The Centre for Applied Genomics

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lawrence Jardine

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

MacGregor Steele

Alberta Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Mariana Silva

Kingston General Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge